{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:04:37Z","timestamp":1780625077285,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,12,20]],"date-time":"2007-12-20T00:00:00Z","timestamp":1198108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00228-007-0421-2","type":"journal-article","created":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T14:41:53Z","timestamp":1198075313000},"page":"337-341","source":"Crossref","is-referenced-by-count":32,"title":["Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation"],"prefix":"10.1007","volume":"64","author":[{"given":"Thrasivoulos George","family":"Tzellos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kouvelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,20]]},"reference":[{"key":"421_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0560.2001.280101.x","volume":"28","author":"AN Crowson","year":"2001","unstructured":"Crowson AN, Magro C (2001) The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 28:1\u201323","journal-title":"J Cutan Pathol"},{"key":"421_CR2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.autrev.2004.10.003","volume":"4","author":"RD Sontheimer","year":"2005","unstructured":"Sontheimer RD (2005) Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 4:253\u2013263","journal-title":"Autoimmun Rev"},{"key":"421_CR3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.autrev.2005.01.003","volume":"4","author":"VP Werth","year":"2005","unstructured":"Werth VP (2005) Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 4:296\u2013302","journal-title":"Autoimmun Rev"},{"key":"421_CR4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.136.8.1033","volume":"136","author":"A Kuhn","year":"2000","unstructured":"Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus-a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033\u20131041","journal-title":"Arch Dermatol"},{"key":"421_CR5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/08916930600886851","volume":"39","author":"HJ Lee","year":"2006","unstructured":"Lee HJ, Sinha AA (2006) Cutaneous lupus erythematosus: Understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoimmunity 39:433\u2013444","journal-title":"Autoimmunity"},{"key":"421_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200506010-00001","volume":"6","author":"A Wozniacka","year":"2005","unstructured":"Wozniacka A, McCauliffe DP (2005) Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol 6:1\u201311","journal-title":"Am J Clin Dermatol"},{"key":"421_CR7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","volume":"153","author":"JJ Wu","year":"2005","unstructured":"Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK (2005) Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 153:254\u2013273","journal-title":"Br J Dermatol"},{"key":"421_CR8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2006.07431.x","volume":"155","author":"A Huber","year":"2006","unstructured":"Huber A, Tuting T, Bauer R, Bieber T, Wenzel J (2006) Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol 155:861\u2013862","journal-title":"Br J Dermatol"},{"key":"421_CR9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1365-2133.2004.05782.x","volume":"150","author":"S Reitamo","year":"2004","unstructured":"Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, Moss C, Dobozy A, Palatsi R; European Tacrolimus Ointment Group (2004) 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 150:554\u2013562","journal-title":"Br J Dermatol"},{"key":"421_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000065843","volume":"205","author":"J Wenzel","year":"2002","unstructured":"Wenzel J, Gerdsen R, Phillipp-Dormston W, Bieber T, Uerlich M (2002) Topical treatment of pyoderma gangrenosum. Dermatology 205:221\u2013223","journal-title":"Dermatology"},{"key":"421_CR11","first-page":"451","volume":"80","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Nishioka K (2000) Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derma Venereol 80:451","journal-title":"Acta Derma Venereol"},{"key":"421_CR12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1067\/mjd.2002.124703","volume":"47","author":"N Uetsu","year":"2002","unstructured":"Uetsu N, Okamoto H, Fujii K, Doi R, Horio T (2002) Treatment of chronic actinic dermatitis with tacrolimus ointment. J Am Acad Dermatol 47:881\u2013884","journal-title":"J Am Acad Dermatol"},{"key":"421_CR13","first-page":"419","volume":"137","author":"EV Lener","year":"2001","unstructured":"Lener EV, Brieva J, Schachter M, West LE, West DP, el-Azhary RA (2001) Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 137:419\u2013422","journal-title":"Arch Dermatol"},{"key":"421_CR14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1368-5031.2005.00587.x","volume":"59","author":"P Gisondi","year":"2005","unstructured":"Gisondi P, Ellis CN, Girolomoni G (2005) Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract 59:969\u2013974","journal-title":"Int J Clin Pract"},{"key":"421_CR15","first-page":"618","volume":"12","author":"AM Marsland","year":"2002","unstructured":"Marsland AM, Griffiths CE (2002) The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 12:618\u2013622","journal-title":"Eur J Dermatol"},{"key":"421_CR16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.0906-6705.2004.00269.x","volume":"13","author":"M Grassberger","year":"2004","unstructured":"Grassberger M, Steinhoff M, Schneider D, Luger TA (2004) Pimecrolimus-an anti inflammatory drug targeting the skin. Exp Dermatol 13:721\u2013730","journal-title":"Exp Dermatol"},{"key":"421_CR17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1742-1241.2003.tb10492.x","volume":"57","author":"RAC Graham-Brown","year":"2003","unstructured":"Graham-Brown RAC, Grassberger M (2003) Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 57:319\u2013327","journal-title":"Int J Clin Pract"},{"key":"421_CR18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF00374076","volume":"287","author":"F Furukawa","year":"1995","unstructured":"Furukawa F, Imamura S, Takigawa M (1995) FK506 Therapeutic effects on lupus dermatoses in autoimmune-prone MRL\/Mp-lrp\/lpr mice. Arch Dermatol Res 287:558\u2013563","journal-title":"Arch Dermatol Res"},{"key":"421_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2133.2001.04076.x","volume":"144","author":"C Queille-Roussel","year":"2001","unstructured":"Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP (2001) The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4\u00a0weeks: a randomized, double-blind controlled study. Br J Dermatol 144:507\u2013513","journal-title":"Br J Dermatol"},{"key":"421_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijpharm.2003.07.013","volume":"269","author":"A Billich","year":"2004","unstructured":"Billich A, Aschauer H, Aszodi A, Stuetz A (2004) Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than CS and tacrolimus. Int J Pharmacol 269:29\u201335","journal-title":"Int J Pharmacol"},{"key":"421_CR21","volume-title":"Evidence based medicine: how to practice and teach EBM","author":"DL Sackett","year":"2000","unstructured":"Sackett DL, Richardson WS, Rosenberg WMC, Haynes RB (2000) Evidence based medicine: how to practice and teach EBM. Churchill-Livingstone, London"},{"key":"421_CR22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2004.01.044","volume":"51","author":"A Kreuter","year":"2004","unstructured":"Kreuter A, Gambichler T, Breuckmann F, Pawlak FM, Stucker M, Bader A, Altmeyer P, Freitag M (2004) Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 51:407\u2013410","journal-title":"J Am Acad Dermatol"},{"key":"421_CR23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/rheumatology\/kei093","volume":"44","author":"A Tlacuilo-Parra","year":"2005","unstructured":"Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F , Soto-Ortiz A, Barba-G\u00fcmez F, Hernandez-Torres M, Salazar-Paramo M (2005) Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology 44:1564\u20131568","journal-title":"Rheumatology"},{"key":"421_CR24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/keh325","volume":"43","author":"CE Lampropoulos","year":"2004","unstructured":"Lampropoulos CE, Sangle S, Harrison P, Hughes GRV, D\u2019Cruz DP (2004) Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology 43:1383\u20131385","journal-title":"Rheumatology"},{"key":"421_CR25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2006.07595.x","volume":"156","author":"TY Tzung","year":"2007","unstructured":"Tzung TY, Liu YS, Chang HW (2007) Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. B J Dermatol 156:191\u2013192","journal-title":"B J Dermatol"},{"key":"421_CR26","first-page":"50","volume":"12","author":"T Yoshimasu","year":"2002","unstructured":"Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F (2002) Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 12:50\u201352","journal-title":"Eur J Dermatol"},{"key":"421_CR27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2007.08177.x","volume":"157","author":"MH Rustin","year":"2007","unstructured":"Rustin MH (2007) The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. B J Dermatol 157:861\u2013873","journal-title":"B J Dermatol"},{"key":"421_CR28","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1592\/phco.27.7.1020","volume":"27","author":"PJ Munzenberger","year":"2007","unstructured":"Munzenberger PJ, Montejo JM (2007) Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 27:1020\u20131028","journal-title":"Pharmacotherapy"},{"key":"421_CR29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","volume":"125","author":"J Albrecht","year":"2005","unstructured":"Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889\u2013894","journal-title":"J Invest Dermatol"},{"key":"421_CR30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8019.2007.00117.x","volume":"20","author":"J Albrecht","year":"2007","unstructured":"Albrecht J, Werth VP (2007) Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 20:93\u2013101","journal-title":"Dermatol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0421-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-007-0421-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0421-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T10:28:38Z","timestamp":1684146518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-007-0421-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,20]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1007\/s00228-007-0421-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,20]]}}}